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Stellingen/propoSitionS 
The public Health impact of Antiviral Therapy  
for Chronic Hepatitis B
1.	 Chronic	hepatitis	B	is	also	a	public	health	problem	in	countries	with	low	hepatitis	B	
endemicity,	because	of	the	high	absolute	number	of	preventable	liver-related	deaths.	
(this	thesis)	
2.	 The	public	health	burden	of	hepatitis	B	could	be	reduced	substantially	by	antiviral	
therapy.	(this	thesis)
3.	 Early	 identification	 through	 screening	 on	 chronic	 HBV	 infection	 is	 essential	 to	
ensuring	 that	 those	 infected	 receive	necessary	care	 to	prevent	or	delay	 the	onset	of	
liver	disease,	and	to	prevent	transmission	of	the	hepatitis	B	virus	to	others.	(this	thesis)
4.	 The	demand	for	care	of	patients	with	chronic	hepatitis	B	will	 increase	as	 screening	
programs	for	this	disease	expand.	(this	thesis)
5.	 Antiviral	therapy	aimed	at	minimizing	or	controlling	viral	resistance	will	have	a	major	
preventive	effect	on	liver-related	morbidity	and	mortality	in	active	chronic	hepatitis	
B	patients.	(this	thesis)
6.	 Chronic	hepatitis	B	patients	 can	 achieve	 a	 significant	 increase	 in	healthy	 life-years	
through	 regular	 medical	 evaluation,	 monitoring	 of	 disease	 progression,	 and	 with	
treatment	preceding	the	development	of	symptoms.	(this	thesis)	
7.	 The	development	of	drugs	for	some	diseases	that	are	prevalent	in	low	income	countries	
might	not	occur	if	manufacturers	cannot	recoup	sunk	costs	by	charging	high	prices	in	
wealthy	countries.	(Differential	pricing	of	drugs,	Lancet)
8.	 QALYs	simply	give	priority	to	interventions	that	offer	the	most	health	benefit	in	terms	
of	measures	people	care	about	‒	more	time	spent	in	good	health.	(Weinstein,	NEJM)
9.	 Healthy	citizens	are	the	greatest	asset	any	country	can	have.	(Winston	Churchill)
10.	 The	people	think	of	wealth	and	power	as	the	greatest	fate,	but	in	this	world	a	spell	of	
health	is	the	best	state.	(Kanuni	Sultan	Suleyman)
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